Citi lowered the firm’s price target on Solid Biosciences (SLDB) to $14 from $16 and keeps a Buy rating on the shares following data from the Phase 1/2 INSPIRE-DUCHENNE trial. The firm says microdystrophin expression after 90 days dropped.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences Faces Regulatory and Financial Challenges Amid FDA Disruptions
- Solid Biosciences’ SGT-003 Therapy Shows Promising Efficacy and Safety, Earning a Buy Rating
- Solid Biosciences price target lowered to $9 from $10 at Barclays
- Solid Biosciences Reports Q3 2025 Results and Clinical Progress
- Solid Biosciences Reports Positive Interim Data on SGT-003